Sanofi caps out-of-pocket insulin cost at $35 for uninsured U.S. patients

Reuters

(Reuters) – French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.

Sanofi said the new price, down from the prior out-of-pocket cost of $99, will be effective from July 1.

U.S. lawmakers have pulled up healthcare companies over rising costs of insulin and the U.S. House of Representatives in March passed a bill capping monthly out-of-pocket insulin costs for those with health insurance at $35.

According to a 2020 Commonwealth Fund study, about two thirds of uninsured insulin users aged 18 to 64 paid the full price – an average of $900 a month – for the life-sustaining medicine.


Sanofi with Eli Lilly and Co and Novo Nordisk make up 90% of the U.S. market for insulin. In 2020, Lilly announced a new co-pay scheme that covers most of its insulin products, capping the out-of-pocket cost for insulin to $35 per month.

Around 37.3 million Americans, or 11.3% of the population, have diabetes, according to the American Diabetes Association.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

tagreuters.com2022binary_LYNXMPEI5S0MD-BASEIMAGE

You appear to be using an ad blocker

Shore News Network is a free website that does not use paywalls or charge for access to original, breaking news content. In order to provide this free service, we rely on advertisements. Please support our journalism by disabling your ad blocker for this website.